Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | TNF | P01375 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96459 | 0.85 | MAPT (0.58) | MAPTMAOAKDM4ENSD2ALDH1A1 | |
| SCHEMBL23544069 | 0.81 | TNF (0.49) | MAPTMAOATNFKDM4ELMNA | |
| SCHEMBL11713358 | 0.80 | KCNA3 (0.47) | MAPTTNFCACNA2D1 | |
| SCHEMBL18355899 | 0.80 | TNF (0.45) | MAPTMAOATNFKDM4EALDH1A1 | |
| SCHEMBL1759351 | 0.78 | MCHR1 (0.51) | MAPTTNFMCHR1 | |
| SCHEMBL25958963 | 0.77 | MAOA (0.54) | MAPTMAOATNFKDM4EALDH1A1 | |
| SCHEMBL21178063 | 0.77 | TNF (0.45) | MAPTMAOATNFKDM4ELMNA | |
| SCHEMBL9272721 | 0.77 | TNF (0.53) | MAPTTNFALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6197255 | 0.77 | KCNA3 (0.47) | MAPTTNFCACNA2D1 | |
| SCHEMBL14599173 | 0.76 | ALDH1A1 (0.50) | MAPTKDM4ENSD2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112500342-A | Synthesis method of 8-methoxyisoquinoline | 苏州康润医药有限公司 | 2021-03-16 | — | — | CN | claimed |
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | SRX CARDIO, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-20240032541-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2024-02-01 | — | — | US | disclosed |
| EP-4210489-A1 | HERBICIDAL COMPOUNDS | Syngenta Crop Protection AG (CH) | 2023-07-19 | — | — | EP | disclosed |
| CN-116018341-A | Herbicidal compounds | 先正达农作物保护股份公司 | 2023-04-25 | — | — | CN | disclosed |
| WO-2022053422-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2022-03-17 | — | — | WO | disclosed |
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| CN-112500342-A | Synthesis method of 8-methoxyisoquinoline | 苏州康润医药有限公司 | 2021-03-16 | — | — | CN | disclosed |
| CN-112500342-A | Synthesis method of 8-methoxyisoquinoline | 苏州康润医药有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-1731507-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | Institut National des Sciences Appliquees de Rouen (INSA) (FR) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006103120-A2 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2006-10-05 | — | — | WO | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| US-20040157865-A1 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-08-12 | — | — | US | disclosed |
| WO-2004007459-A2 | NAPHTHOL, QUINOLINE AND ISOQUINOLINE-DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | WO | disclosed |
| US-4273862-A | ANIONIC CYANINE DYE, HYDROQUINONE FRBRLOPRT | MITSUBISHI PAPER MILLS, LTD. (JP) | 1981-06-16 | — | — | US | disclosed |
| US-4259439-A | DIMETHINECYANINE DYE SENSITIZER | MITSUBISHI PAPER MILLS, LTD. (JP) | 1981-03-31 | — | — | US | disclosed |
| US-4147554-A | 5,6-DIHYDRO-PYRROLO(2,1-A)ISOQUINOLINES | MITSUBISHI PAPER MILLS, LTD. (JP) | 1979-04-03 | — | — | US | disclosed |
| US-4134769-A | BETAINE AND ANIONIC TYPE CYANINE DYES | MITSUBISHI PAPER MILLS, LTD. (JP) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | PCSK9, PCSK6, PCSK7 | MAPT 2710/4885MAOA 2100/4885TNF 2814/4885 |
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | SARM1, NNMT, NQO1 | MAPT 105/4885MAOA 888/4885TNF 4685/4885 |
| US-20240032541-A1 | HERBICIDAL COMPOUNDS | HAX1, DDT, MTX1 | MAPT 4243/4885MAOA 1519/4885TNF 4514/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | MAPT 62/4885MAOA 2600/4885TNF 4202/4885 |
| US-20040157865-A1 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | OPRL1, VRK1, OPRK1 | MAPT 3341/4885MAOA 4236/4885TNF 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.